NEU neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-73

  1. 2,524 Posts.
    lightbulb Created with Sketch. 690
    I agree. I wouldn't sell at these prices even if we didn't have NNZ-2256!

    Daybue guidance (70m AUD) on a 40 forward PE = 2.8B AUD. We also have 250m cash on top of this. Zero value assigned to NNZ-2256

    This 40 forward PE is very reasonable because:

    • Peak sales won't be achieved in the first full year, so there will be growth in the coming years (North America)
    • Additional geographies will add more sales, even if the pricing isn't as strong as North America (Europe and Japan, EMA)
    • Milestone payments aren't included in my calculations, but they go straight to earnings. These milestones are reasonable and many of them can be hit within a reasonable time frame. An additional 77m~ is projected to be comfortably hit based on the guidance already provided.
    • PRV isn't included in these calculations.
    • We have very low expenses compared to peers and, our expenses spent on R&D are partially a tax deduction.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.54
Change
0.100(0.80%)
Mkt cap ! $1.559B
Open High Low Value Volume
$12.44 $12.73 $12.13 $11.07M 885.6K

Buyers (Bids)

No. Vol. Price($)
1 1215 $12.52
 

Sellers (Offers)

Price($) Vol. No.
$12.54 804 1
View Market Depth
Last trade - 16.10pm 20/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.